logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

WCLC 2019 – Pembrolizumab monotherapy in previously untreated NSCLC: very first results in Chinese patients

KEYNOTE-042 China study showed significative improvements in survival with first-line immunotherapy compared to chemotherapy, consistent with global results